← All trials
NCT06211283
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2023
- Primary completion
- Oct 20, 2023
- Completion date
- Nov 1, 2023
- First posted
- Jan 18, 2024
- Last posted
- Jan 22, 2024
- Enrollment
- 28
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Desitin Arzneimittel GmbHLead sponsor
- BioPharma ServicesCollaborator
- BioPharma ServicesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.